Page last updated: 2024-11-11
juniperonic acid
Description
juniperonic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(5Z,11Z,14Z,17Z)-icosatetraenoic acid : An icosatetraenoic acid in which the four double bonds have Z configuration and are located at positions 5, 11, 14 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 5312543 |
CHEBI ID | 82835 |
SCHEMBL ID | 6119205 |
MeSH ID | M0403147 |
Synonyms (13)
Synonym |
LMFA01030394 , |
juniperonic acid |
c20:4n-3,6,9,15 |
5z,11z,14z,17z-eicosatetraenoic acid |
(5z,11z,14z,17z)-icosa-5,11,14,17-tetraenoic acid |
all-cis-5,11,14,17-eicosatetraenoic acid |
all-cis-5,11,14,17-icosatetraenoic acid |
(5z,11z,14z,17z)-icosatetraenoic acid |
(5z,11z,14z,17z)-eicosatetraenoic acid |
CHEBI:82835 |
SCHEMBL6119205 |
5(z),11(z),14(z),17(z)-eicosatetraenoic acid |
Q27156397 |
Roles (1)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
icosatetraenoic acid | A 20-carbon, polyunsaturated fatty acid having four double bonds at unspecified positions. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.43 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |